Theriva Biologics Secures Up to $38M in SYN-020 Licensing Deal With Rasayana Therapeutics
Market Chameleon (Thu, 19-Feb 10:34 AM)
EMA Endorses Theriva Biologics’ Phase 3 VCN-01 Trial Design for Metastatic Pancreatic Cancer—Path Cleared for Innovative Approach
Market Chameleon (Mon, 29-Dec 10:32 AM)
